Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock.

A number of other research analysts also recently weighed in on HOWL. JMP Securities reiterated a market outperform rating and issued a $12.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th. Wedbush reaffirmed an outperform rating and issued a $9.00 price target on shares of Werewolf Therapeutics in a research note on Monday, June 3rd.

Werewolf Therapeutics Stock Down 12.3 %

Shares of HOWL opened at $2.06 on Tuesday. The stock’s 50-day moving average price is $4.35 and its 200-day moving average price is $5.11. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $89.53 million, a price-to-earnings ratio of -1.89 and a beta of 0.47. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The firm had revenue of $0.74 million for the quarter, compared to analyst estimates of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. On average, sell-side analysts predict that Werewolf Therapeutics will post -1.52 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Financial Perspectives Inc boosted its position in shares of Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares during the period. Certuity LLC purchased a new position in Werewolf Therapeutics in the fourth quarter valued at $39,000. Lighthouse Investment Partners LLC purchased a new stake in Werewolf Therapeutics during the 4th quarter worth about $87,000. Denali Advisors LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at about $172,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after buying an additional 94,212 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.